NCT03932526 is a Phase 2 clinical trial of Vinorelbine + Apatinib in Triple-negative Breast Cancer, sponsored by Liaoning Cancer Hospital & Institute.

Who is sponsoring NCT03932526?

NCT03932526 is sponsored by Liaoning Cancer Hospital & Institute.

What drugs are being tested in NCT03932526?

Interventions in NCT03932526: Vinorelbine + placebo, Vinorelbine + Apatinib.

What condition does NCT03932526 study?

NCT03932526 studies Triple-negative Breast Cancer.

Is NCT03932526 still recruiting?

NCT03932526 is currently status unknown. Last updated 30 April 2019.

Last reviewed 2019-04-30 · How we verify

NCT03932526

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Status unknown Phase 2 Last updated 30 April 2019

What this trial tests

Phase 2 trial testing Vinorelbine + placebo in Triple-negative Breast Cancer in 184 participants. Status unknown.

Timeline

24 June 2019

Primary endpoint
12 December 2022

26 June 2023

Quick facts

Lead sponsor	Liaoning Cancer Hospital & Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	184
Start date	24 June 2019
Primary completion	12 December 2022
Estimated completion	26 June 2023

Drugs / interventions tested

Vinorelbine + placebo — full drug profile →
Vinorelbine + Apatinib — full drug profile →

Conditions studied

Triple-negative Breast Cancer — all drugs for Triple-negative Breast Cancer →

Sponsor

Liaoning Cancer Hospital & Institute

Who can join

Adults 18 to 70, female only, with Triple-negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the therapeutic effect of vinorelbine used alone or combined with apatinib mesylate for recurrent or metastatic TNBC patients who have at least received one chemotherapy regimen, including anthracyclines and taxanes, providing clinical evidence for multi-line treatment options for advanced TNBC.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y, Zhang H, Merkher Y, Chen L, et al · · 2022 · cited 643× · PMID 36038913 · DOI 10.1186/s13045-022-01341-0
Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
Ferrari P, Scatena C, Ghilli M, Bargagna I, et al · · 2022 · cited 143× · PMID 35163586 · DOI 10.3390/ijms23031665
Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
Wu S, Zhang L, Li H, Xu J, et al · · 2020 · cited 9× · PMID 32448335 · DOI 10.1186/s13063-020-04342-x
Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
Wu S, Zhang L, Li H, Xu J, et al · · 2020 · DOI 10.21203/rs.2.11817/v6

Verify or expand the search:

Other recruiting trials for Triple-negative Breast Cancer

Currently open trials in the same condition.

NCT07510802 — Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC · Phase 1, PHASE2 · recruiting
NCT07045311 — JS207 Combination Therapy in Triple-negative Breast Cancer · Phase 2 · recruiting
NCT06078384 — Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC · Phase 2 · recruiting
NCT06817525 — Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC · Phase 2 · recruiting
NCT06371274 — A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. · NA · recruiting

Other Liaoning Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07161453 — Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinom · Phase 4 · not yet recruiting
NCT07132528 — Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After · Phase 4 · not yet recruiting
NCT07149181 — Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regim · Phase 4 · not yet recruiting
NCT06908733 — Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC · Phase 2 · not yet recruiting
NCT06764251 — Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Ade · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03932526 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Liaoning Cancer Hospital & Institute
Last refreshed: 30 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03932526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing